Sarah Benezech
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Benezech has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
- Thierry Walzer
CIRI, International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France
7 shared publications - Alexandre Belot
Centre International de Recherche en Infectiologie, Inserm, U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France
5 shared publications - Antoine Marçais
CIRI, Centre International de Recherche en Infectiologie, (Team LYACTS), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France
5 shared publications Annabelle Drouillard
CIRI, Centre International de Recherche en Infectiologie, (Team Lyacts), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France
3 shared publications- Carine Domenech
Department of Pediatric Hematology and Oncology, IHOP, Hospices Civils de Lyon, Lyon 1 University, Lyon, France
3 shared publications - Anaïs Nombel
Inserm, U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Lyon, France
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
Real-World Use of Dinutuximab Beta for High-Risk Neuroblastoma in Clinical Settings in France: The QUATUOR Study
Dinutuximab beta (DB) is recommended for maintenance therapy in high-risk neuroblastoma (HR-NB) in Europe. In France, early access to DB was provided in the Temporary Use Authorization (ATU) program. The QUATUOR (Qarziba Use ATU Outcomes Research) study is an observational, multicenter, retrospective study that evaluated the effectiveness and safety of DB in HR-NB patients who received DB in maintenance between February 2017 and August 2018 in real-world clinical settings in France as part of the ATU program. Fourteen patients received DB in the frontline and 17 in the refractory/relapsed setting. In the frontline group, 2-year EFS and OS rates were 64.3% (95% CI: 34.3-83.3%) and 78.6% (95% CI: 47.3-92.5%), respectively, and in the relapsed/refractory group, 57.5% (95% CI: 30.7-77.2%) and 80.9% (95% CI: 51.3-93.5%), respectively. Complete or partial response of the metastatic sites was maintained by 23/31 evaluable patients at the end of treatment. Overall, DB was effective, with acceptable tolerability, in patients with HR-NB treated as part of the ATU program in France. This study demonstrates the importance of successful collaboration between national health authorities, pharmaceutical companies, physicians, and the neuroblastoma community to provide early access to innovative treatments.
- 15 October 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
Open AccessReal-World Use of Dinutuximab Beta for High-Risk Neuroblastoma in Clinical Settings in France: The QUATUOR Study
Dinutuximab beta (DB) is recommended for maintenance therapy in high-risk neuroblastoma (HR-NB) in Europe. In France, early access to DB was provided in the Temporary Use Authorization (ATU) program. The QUATUOR (Qarziba Use ATU Outcomes Research) study is an observational, multicenter, retrospective study that evaluated the effectiveness and safety of DB in HR-NB patients who received DB in maintenance between February 2017 and August 2018 in real-world clinical settings in France as part of the ATU program. Fourteen patients received DB in the frontline and 17 in the refractory/relapsed setting. In the frontline group, 2-year EFS and OS rates were 64.3% (95% CI: 34.3-83.3%) and 78.6% (95% CI: 47.3-92.5%), respectively, and in the relapsed/refractory group, 57.5% (95% CI: 30.7-77.2%) and 80.9% (95% CI: 51.3-93.5%), respectively. Complete or partial response of the metastatic sites was maintained by 23/31 evaluable patients at the end of treatment. Overall, DB was effective, with acceptable tolerability, in patients with HR-NB treated as part of the ATU program in France. This study demonstrates the importance of successful collaboration between national health authorities, pharmaceutical companies, physicians, and the neuroblastoma community to provide early access to innovative treatments.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des lymphocytes Natural Killer humains en contexte de signalisation Interféron de type I aigue et chronique
Les lymphocytes NK (Natural Killer) occupent une place centrale dans l’immunité antivirale et antitumorale précoce, grâce à leur capacité à reconnaître et éliminer rapidement les cellules infectées ou transformées. Outre cette fonction de cytotoxicités, les lymphocytes NK activées sécrètent des cytokines participant à l’orchestration de la réponse immunitaire. Si la compréhension des mécanismes conduisant à l’activation des lymphocytes NK a beaucoup progressé grâce aux modèles animaux et in vitro, l’objectivation et la transposition de ces processus à la physiologie humaine reste lacunaire. Dans la première partie de ce travail, nous avons exploré ces mécanismes d’activation en analysant la réponse lymphocytaire NK au cours d’infections virales aigues par le SARS-CoV-2, survenues dans une cohorte de patients vaccinés et présentant une forme modérée de COVID-19. Cette étude a mis en évidence une activation marquée des lymphocytes NK chez les patients infectés, corrélée à une augmentation des taux plasmatiques d’IFN-α et à l’expression de marqueurs d’activation tels que CD69 et CD38. Cette activation était consécutive à une signalisation par l’interleukine-15. Sur le plan fonctionnel, les lymphocytes NK des patients infectés présentaient une cytotoxicité supérieure à celle de témoins sains. Une exploration cytométrique a montré une reprogrammation métabolique globale, associant une augmentation à la fois de la glycolyse et du métabolisme mitochondrial. Cette reprogrammation était associée à une surexpression du régulateur métabolique carnitine palmitoyltransférase 1A (CPT1A) dont le niveau était corrélé positivement au niveau d’activation des lymphocytes NK évalué par le niveau d’expression de CD38. L’augmentation d’expression de CPT1A dans les lymphocytes NK activés était également corrélée à l’absorption des acides gras à chaines longues, témoignant témoignant d’une intensification du métabolisme de β-oxydation lipidique en contexte d’infection virale. Ces remaniements, spécifiques des lymphocytes NK et absents dans les lymphocytes B et T, témoignent d’une activation métabolique précoce combinant glycolyse et oxydation lipidique, associée à un renforcement des fonctions effectrices au cours de l’infection virale aiguë. Dans la seconde partie de ce travail, nous avons étudié les conséquences d’une signalisation interféron de type I chronique dans le contexte des interféronopathies pédiatriques, pathologies rares caractérisées par une activation soutenue de la voie IFN. Contrairement au bénéfice transitoire observé lors des infections aiguës, une stimulation prolongée s’est révélée délétère pour les fonctions NK. Nous avons mis en évidence une altération significative de la cytotoxicité dépendante des anticorps (ADCC), parallèlement à une diminution de l’expression du récepteur FcγRIIIa (CD16), molécule clé dans la médiation de cette fonction. Cette perte fonctionnelle souligne l’effet paradoxal d’une signalisation interféron persistante. Ces observations ouvrent des perspectives importantes sur la compréhension des déficits immunitaires secondaires aux interféronopathies et pourraient contribuer à l’élaboration de stratégies thérapeutiques visant à restaurer la fonction NK dans ces contextes pathologiques. En conclusion, ce travail questionne la dualité de l’impact de la signalisation interféron sur les lymphocytes NK : bénéfique lorsqu’elle est transitoire lors d’une réponse antivirale aiguë, et délétère lorsqu’elle devient chronique, comme dans les interféronopathies. L’ensemble de nos résultats renforce l’idée que le métabolisme et la signalisation cytokiniques sont des déterminants essentiels de la fonctionnalité des lymphocytes NK, et la caractérisation de ces régulations est essentielle dans la perspective de développement de thérapeutiques visant à moduler la réponse immunitaire innée.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des lymphocytes Natural Killer humains en contexte de signalisation Interféron de type I aigue et chronique
Les lymphocytes NK (Natural Killer) occupent une place centrale dans l’immunité antivirale et antitumorale précoce, grâce à leur capacité à reconnaître et éliminer rapidement les cellules infectées ou transformées. Outre cette fonction de cytotoxicités, les lymphocytes NK activées sécrètent des cytokines participant à l’orchestration de la réponse immunitaire. Si la compréhension des mécanismes conduisant à l’activation des lymphocytes NK a beaucoup progressé grâce aux modèles animaux et in vitro, l’objectivation et la transposition de ces processus à la physiologie humaine reste lacunaire. Dans la première partie de ce travail, nous avons exploré ces mécanismes d’activation en analysant la réponse lymphocytaire NK au cours d’infections virales aigues par le SARS-CoV-2, survenues dans une cohorte de patients vaccinés et présentant une forme modérée de COVID-19. Cette étude a mis en évidence une activation marquée des lymphocytes NK chez les patients infectés, corrélée à une augmentation des taux plasmatiques d’IFN-α et à l’expression de marqueurs d’activation tels que CD69 et CD38. Cette activation était consécutive à une signalisation par l’interleukine-15. Sur le plan fonctionnel, les lymphocytes NK des patients infectés présentaient une cytotoxicité supérieure à celle de témoins sains. Une exploration cytométrique a montré une reprogrammation métabolique globale, associant une augmentation à la fois de la glycolyse et du métabolisme mitochondrial. Cette reprogrammation était associée à une surexpression du régulateur métabolique carnitine palmitoyltransférase 1A (CPT1A) dont le niveau était corrélé positivement au niveau d’activation des lymphocytes NK évalué par le niveau d’expression de CD38. L’augmentation d’expression de CPT1A dans les lymphocytes NK activés était également corrélée à l’absorption des acides gras à chaines longues, témoignant témoignant d’une intensification du métabolisme de β-oxydation lipidique en contexte d’infection virale. Ces remaniements, spécifiques des lymphocytes NK et absents dans les lymphocytes B et T, témoignent d’une activation métabolique précoce combinant glycolyse et oxydation lipidique, associée à un renforcement des fonctions effectrices au cours de l’infection virale aiguë. Dans la seconde partie de ce travail, nous avons étudié les conséquences d’une signalisation interféron de type I chronique dans le contexte des interféronopathies pédiatriques, pathologies rares caractérisées par une activation soutenue de la voie IFN. Contrairement au bénéfice transitoire observé lors des infections aiguës, une stimulation prolongée s’est révélée délétère pour les fonctions NK. Nous avons mis en évidence une altération significative de la cytotoxicité dépendante des anticorps (ADCC), parallèlement à une diminution de l’expression du récepteur FcγRIIIa (CD16), molécule clé dans la médiation de cette fonction. Cette perte fonctionnelle souligne l’effet paradoxal d’une signalisation interféron persistante. Ces observations ouvrent des perspectives importantes sur la compréhension des déficits immunitaires secondaires aux interféronopathies et pourraient contribuer à l’élaboration de stratégies thérapeutiques visant à restaurer la fonction NK dans ces contextes pathologiques. En conclusion, ce travail questionne la dualité de l’impact de la signalisation interféron sur les lymphocytes NK : bénéfique lorsqu’elle est transitoire lors d’une réponse antivirale aiguë, et délétère lorsqu’elle devient chronique, comme dans les interféronopathies. L’ensemble de nos résultats renforce l’idée que le métabolisme et la signalisation cytokiniques sont des déterminants essentiels de la fonctionnalité des lymphocytes NK, et la caractérisation de ces régulations est essentielle dans la perspective de développement de thérapeutiques visant à moduler la réponse immunitaire innée.
- Top Cited PapersOpen Access
- 12 January 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Novel TLR7 gain-of-function variant and review of the associated disease spectrum
Early-onset systemic lupus erythematosus (SLE) is frequently associated with a more severe phenotype and may be linked to monogenic causes in at least 10% of all juvenile SLE cases. Recent advances in immunogenetics have identified Mendelian variants linked to inborn errors of immunity, underlying SLE. Toll-like receptor 7 (TLR7), an endosomal RNA sensor, has emerged as a key contributor to lupus pathogenesis through aberrant activation. We report a novel P435S gain-of-function (GOF) variant in TLR7 identified in a female patient presenting with early-onset SLE, recurrent infection, and neuroinflammatory features. Functional assays demonstrated the gain-of-function effect, confirming its pathogenicity and supporting its role in disease onset and progression. To further define the clinical spectrum of TLR7 GOF-associated disease, we conducted a systematic review of 11 additional reported cases, highlighting shared and divergent phenotypic features. These findings expand the understanding of TLR7-mediated autoimmunity and underscore the importance of genetic screening in early-onset SLE with atypical features.
- 12 January 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Top Cited PapersOpen AccessNovel TLR7 gain-of-function variant and review of the associated disease spectrum
Early-onset systemic lupus erythematosus (SLE) is frequently associated with a more severe phenotype and may be linked to monogenic causes in at least 10% of all juvenile SLE cases. Recent advances in immunogenetics have identified Mendelian variants linked to inborn errors of immunity, underlying SLE. Toll-like receptor 7 (TLR7), an endosomal RNA sensor, has emerged as a key contributor to lupus pathogenesis through aberrant activation. We report a novel P435S gain-of-function (GOF) variant in TLR7 identified in a female patient presenting with early-onset SLE, recurrent infection, and neuroinflammatory features. Functional assays demonstrated the gain-of-function effect, confirming its pathogenicity and supporting its role in disease onset and progression. To further define the clinical spectrum of TLR7 GOF-associated disease, we conducted a systematic review of 11 additional reported cases, highlighting shared and divergent phenotypic features. These findings expand the understanding of TLR7-mediated autoimmunity and underscore the importance of genetic screening in early-onset SLE with atypical features.
- 16 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (904) , eadq8778
Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1
The multiprotein complex mTORC1 is essential for the increase in protein synthesis and bioenergetic metabolism that supports the proliferation of many cell types, including natural killer (NK) cells, which are important innate effectors of the antitumoral response. Here, we investigated the mechanisms of mTORC1 activation in NK cells by interleukin-15 (IL-15) and IL-18, which promote NK cell function and are components of a cytokine cocktail used to preactivate NK cells for cancer immunotherapy. Through genetic and pharmacological approaches, we showed that IL-15 activated mTORC1 through the PI3K/Akt/ERK pathway, whereas IL-18 signaled through the p38 effectors MK2 and MK3 in both murine and human primary NK cells. Both pathways synergized to promote NK cell proliferation and effector functions in an mTORC1-dependent manner. Moreover, both pathways operated independently of the inhibitor TSC and the activator Rheb, revealing a noncanonical mode of mTORC1 activation by cytokines. Treating mice with IL-15 and IL-18 in combination led to increased NK cell numbers and improved antitumoral activity, suggesting that this cytokine combination could be exploited to enhance NK cell potential in therapeutic settings.
- 16 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (904) , eadq8778
Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1
The multiprotein complex mTORC1 is essential for the increase in protein synthesis and bioenergetic metabolism that supports the proliferation of many cell types, including natural killer (NK) cells, which are important innate effectors of the antitumoral response. Here, we investigated the mechanisms of mTORC1 activation in NK cells by interleukin-15 (IL-15) and IL-18, which promote NK cell function and are components of a cytokine cocktail used to preactivate NK cells for cancer immunotherapy. Through genetic and pharmacological approaches, we showed that IL-15 activated mTORC1 through the PI3K/Akt/ERK pathway, whereas IL-18 signaled through the p38 effectors MK2 and MK3 in both murine and human primary NK cells. Both pathways synergized to promote NK cell proliferation and effector functions in an mTORC1-dependent manner. Moreover, both pathways operated independently of the inhibitor TSC and the activator Rheb, revealing a noncanonical mode of mTORC1 activation by cytokines. Treating mice with IL-15 and IL-18 in combination led to increased NK cell numbers and improved antitumoral activity, suggesting that this cytokine combination could be exploited to enhance NK cell potential in therapeutic settings.
- Open Access
Immunological and clinical markers of post-acute sequelae of COVID-19: Insights from mild and severe cases six months post-infection
SUMMARY: Post-acute sequelae of COVID-19 (PASC) is a complex and multifaceted clinical challenge requiring to emphasize its underlying pathophysiological mechanisms. This study assessed hundreds of virological, serological, immunological, and tissue damage biomarkers in two patient cohorts who experienced mild (n=270) or severe (n=188) COVID-19, 6 to 9 months post-initial infection, and in which 40% and 57.4% of patients, respectively, developed PASC. Blood analysis showed that mains differences observed in humoral, viral, and biological biomarkers were associated with the initial COVID-19 severity, rather than being specifically linked to PASC. However, patients with PASC displayed altered CD4 + and CD8 + memory T-cell subsets, with higher cytokine-secreting cells and increased terminally differentiated CD45RA + effector memory T cells (TEMRA). Elevated SARS-CoV-2-specific T cells responsive to nucleocapsid/membrane proteins with a TEMRA phenotype were also observed. A random forest model identified these features and initial symptom duration as top variables discriminating PASC, achieving over 80% classification accuracy. Highlights: Nine months post-initial SARS-CoV-2 infection, over 40% of patients developed PASC Regardless of PASC, the initial disease form influenced the main immune differences PASC led to altered memory T-cell subsets with elevated TEMRA phenotype PASC presence is associated with disease form, initial symptom count and duration
Open AccessImmunological and clinical markers of post-acute sequelae of COVID-19: Insights from mild and severe cases six months post-infection
SUMMARY: Post-acute sequelae of COVID-19 (PASC) is a complex and multifaceted clinical challenge requiring to emphasize its underlying pathophysiological mechanisms. This study assessed hundreds of virological, serological, immunological, and tissue damage biomarkers in two patient cohorts who experienced mild (n=270) or severe (n=188) COVID-19, 6 to 9 months post-initial infection, and in which 40% and 57.4% of patients, respectively, developed PASC. Blood analysis showed that mains differences observed in humoral, viral, and biological biomarkers were associated with the initial COVID-19 severity, rather than being specifically linked to PASC. However, patients with PASC displayed altered CD4 + and CD8 + memory T-cell subsets, with higher cytokine-secreting cells and increased terminally differentiated CD45RA + effector memory T cells (TEMRA). Elevated SARS-CoV-2-specific T cells responsive to nucleocapsid/membrane proteins with a TEMRA phenotype were also observed. A random forest model identified these features and initial symptom duration as top variables discriminating PASC, achieving over 80% classification accuracy. Highlights: Nine months post-initial SARS-CoV-2 infection, over 40% of patients developed PASC Regardless of PASC, the initial disease form influenced the main immune differences PASC led to altered memory T-cell subsets with elevated TEMRA phenotype PASC presence is associated with disease form, initial symptom count and duration
- 3 January 2025
- Published by Springer Nature
- p. 1-31
Phenotypic Heterogeneity of Dysfunctional Natural Killer Cells During Chronic Infection or Cancer
- 3 January 2025
- Published by Springer Nature
- p. 1-31
Phenotypic Heterogeneity of Dysfunctional Natural Killer Cells During Chronic Infection or Cancer
- 3 January 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (2) , 336-347
Pivotal role of exogenous pyruvate in human natural killer cell metabolism
Resting natural killer (NK) cells display immediate effector functions after recognizing transformed or infected cells. The environmental nutrients and metabolic requirements to sustain these functions are not fully understood. Here, we show that NK cells rely on the use of extracellular pyruvate to support effector functions, signal transduction and cell viability. Glucose-derived carbons do not generate endogenous pyruvate. Consequently, NK cells import extracellular pyruvate that is reduced to lactate to regenerate glycolytic NAD+ and is oxidized in the tricarboxylic acid (TCA) cycle to produce ATP. This supports serine production through phosphoglycerate dehydrogenase, a pathway required for optimal proliferation following cytokine stimulation but dispensable for effector functions. In addition, like mouse NK cells, human NK cells rely on a citrate–malate configuration of the TCA cycle that is not fed by glutamine. Moreover, supraphysiologic pyruvate concentrations dose-dependently increase the effector functions of NK cells. Overall, this study highlights the role of exogenous pyruvate in NK cell biology, providing knowledge that could be exploited to boost NK cell potential in therapeutic settings.
- 3 January 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (2) , 336-347
Pivotal role of exogenous pyruvate in human natural killer cell metabolism
Resting natural killer (NK) cells display immediate effector functions after recognizing transformed or infected cells. The environmental nutrients and metabolic requirements to sustain these functions are not fully understood. Here, we show that NK cells rely on the use of extracellular pyruvate to support effector functions, signal transduction and cell viability. Glucose-derived carbons do not generate endogenous pyruvate. Consequently, NK cells import extracellular pyruvate that is reduced to lactate to regenerate glycolytic NAD+ and is oxidized in the tricarboxylic acid (TCA) cycle to produce ATP. This supports serine production through phosphoglycerate dehydrogenase, a pathway required for optimal proliferation following cytokine stimulation but dispensable for effector functions. In addition, like mouse NK cells, human NK cells rely on a citrate–malate configuration of the TCA cycle that is not fed by glutamine. Moreover, supraphysiologic pyruvate concentrations dose-dependently increase the effector functions of NK cells. Overall, this study highlights the role of exogenous pyruvate in NK cell biology, providing knowledge that could be exploited to boost NK cell potential in therapeutic settings.
- Open Access
- 30 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (35) , eadn0164
Tumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints
Natural killer (NK) cells often become dysfunctional during tumor progression, but the molecular mechanisms underlying this phenotype remain unclear. To explore this phenomenon, we set up mouse lymphoma models activating or not activating NK cells. Both tumor types elicited type I interferon production, leading to the expression of a T cell exhaustion-like signature in NK cells, which included immune checkpoint proteins (ICPs). However, NK cell dysfunction occurred exclusively in the tumor model that triggered NK cell activation. Moreover, ICP-positive NK cells demonstrated heightened reactivity compared to negative ones. Furthermore, the onset of NK cell dysfunction was swift and temporally dissociated from ICPs induction, which occurred as a later event during tumor growth. Last, NK cell responsiveness was restored when stimulation was discontinued, and interleukin-15 had a positive impact on this reversion. Therefore, our data demonstrate that the reactivity of NK cells is dynamically controlled and that NK cell dysfunction is a reversible process uncoupled from the expression of ICPs.
- 30 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (35) , eadn0164
Open AccessTumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints
Natural killer (NK) cells often become dysfunctional during tumor progression, but the molecular mechanisms underlying this phenotype remain unclear. To explore this phenomenon, we set up mouse lymphoma models activating or not activating NK cells. Both tumor types elicited type I interferon production, leading to the expression of a T cell exhaustion-like signature in NK cells, which included immune checkpoint proteins (ICPs). However, NK cell dysfunction occurred exclusively in the tumor model that triggered NK cell activation. Moreover, ICP-positive NK cells demonstrated heightened reactivity compared to negative ones. Furthermore, the onset of NK cell dysfunction was swift and temporally dissociated from ICPs induction, which occurred as a later event during tumor growth. Last, NK cell responsiveness was restored when stimulation was discontinued, and interleukin-15 had a positive impact on this reversion. Therefore, our data demonstrate that the reactivity of NK cells is dynamically controlled and that NK cell dysfunction is a reversible process uncoupled from the expression of ICPs.
- 30 November 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 389 (22) , 2105-2107
Pre–Covid-19, SARS-CoV-2–Negative Multisystem Inflammatory Syndrome in Children
- 30 November 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 389 (22) , 2105-2107
Pre–Covid-19, SARS-CoV-2–Negative Multisystem Inflammatory Syndrome in Children
- Open Access
- 4 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2702
Rescue of Pap-Mas in Systemic JIA Using Janus Kinase Inhibitors, Case Report and Systematic Review
Introduction: Biological disease-modifying anti-rheumatic drugs (bDMARDs) targeting interleukin (IL)-6 and IL-1β represent a steroid-sparing first-line therapy used in systemic-onset juvenile idiopathic arthritis (sJIA). Recently, the occurrence of pulmonary alveolar proteinosis (PAP) in sJIA patients was reported with early-onset and exposure to bDMARDs as potential risk factors. We report on a new case with longitudinal immunomonitoring successfully treated by Janus Kinase inhibitors (JAKi) and review past clinical descriptions of this new entity. Methods: We report one case of pulmonary alveolar proteinosis and macrophage activation syndrome (PAP-MAS) with longitudinal immunomonitoring. We then conducted a review of the literature of seven publications reporting 107 cases of PAP-MAS sJIA, and included the main characteristics and evolution under treatment. Results: Of the seven articles analyzed, the incidence of PAP-MAS among sJIA patients varied from 1.28% to 12.9%. We report here a single case among a cohort of 537 sJIA patients followed in the pediatric department of the Hospices Civils de Lyon over the last 15 years. This child presented with all clinical and immunological characteristics of PAP-MAS. After several lines of treatment, he benefited from JAKi and improved with respect to both systemic symptoms and lung disease. In the literature, strategies with monoclonal antibodies targeting either INF-γ or IL-1β/IL-18 have been tested with variable results. Orally taken JAKi presents the advantage of targeting multiple cytokines and avoiding parenteral injections of monoclonal antibodies that may contribute to the pathogenesis. Conclusions: JAKi represent a promising option in the treatment of lung disease associated with sJIA.
- 4 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2702
Open AccessRescue of Pap-Mas in Systemic JIA Using Janus Kinase Inhibitors, Case Report and Systematic Review
Introduction: Biological disease-modifying anti-rheumatic drugs (bDMARDs) targeting interleukin (IL)-6 and IL-1β represent a steroid-sparing first-line therapy used in systemic-onset juvenile idiopathic arthritis (sJIA). Recently, the occurrence of pulmonary alveolar proteinosis (PAP) in sJIA patients was reported with early-onset and exposure to bDMARDs as potential risk factors. We report on a new case with longitudinal immunomonitoring successfully treated by Janus Kinase inhibitors (JAKi) and review past clinical descriptions of this new entity. Methods: We report one case of pulmonary alveolar proteinosis and macrophage activation syndrome (PAP-MAS) with longitudinal immunomonitoring. We then conducted a review of the literature of seven publications reporting 107 cases of PAP-MAS sJIA, and included the main characteristics and evolution under treatment. Results: Of the seven articles analyzed, the incidence of PAP-MAS among sJIA patients varied from 1.28% to 12.9%. We report here a single case among a cohort of 537 sJIA patients followed in the pediatric department of the Hospices Civils de Lyon over the last 15 years. This child presented with all clinical and immunological characteristics of PAP-MAS. After several lines of treatment, he benefited from JAKi and improved with respect to both systemic symptoms and lung disease. In the literature, strategies with monoclonal antibodies targeting either INF-γ or IL-1β/IL-18 have been tested with variable results. Orally taken JAKi presents the advantage of targeting multiple cytokines and avoiding parenteral injections of monoclonal antibodies that may contribute to the pathogenesis. Conclusions: JAKi represent a promising option in the treatment of lung disease associated with sJIA.